Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. lymphodrain

LymphoDrain SIGNED

First subcutaneous implant to treat lymphedema. Definitive solution for chronic lymphedema

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 LymphoDrain project word cloud

Explore the words cloud of the LymphoDrain project. It provides you a very rough idea of what is the project "LymphoDrain" about.

consciously    masschallenge    lymphodrain    implantable    team    underlying    segment    moment    treatment    million    micro    grant    accelerator    cti    animal    federal    patented    disorders    replace    competition    winner    magnetically    population    cover    suffer    top3    hospital    venture    lack    national    chuv    initial    marco    chronic    2017    financial    cancer    draining    situation    disruptive    people    epfl    finalist    received    care    pisano    function    created    innovation    15    switzerland    international    multidisciplinary    uses    attracting    bioengineering    qualified    perspective    fit    dr    melody    led    models    invention    triacca    business    lymphedema    off    market    vision    catheters    vessel    recognition    2016    coupled    tested    clinical    lymphatica    treatments    pump    termis    prof    awards    medtech    participated    presently    swartz    kick    unstoppable    company    valentina    health    spin    lymphatic    designed    trajectory    successfully    stage    ait    laboratory    positions    university    treat    plan    swiss    lausanne    imagine   

Project "LymphoDrain" data sheet

The following table provides information about the project.

Coordinator		 LYMPHATICA MEDTECH SA 

Organization address
address: BATIMENT E EPFL INNOVATION PARK
city: LAUSANNE
postcode: 1015
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Switzerland [CH]
 Project website http://www.lymphatica.ch
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2018-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LYMPHATICA MEDTECH SA CH (LAUSANNE) coordinator 50˙000.00

Map

 Project objective

Lymphatica Medtech S.A. is a spin-off company created in 2017, from the Swiss Federal Institute of Technology in Lausanne (EPFL) and the Lausanne University Hospital (CHUV). It has designed and patented “LymphoDrain” a novel implantable system to replace the lymphatic vessel draining function to treat lymphatic disorders, in particular chronic lymphedema. It uses an underlying technology based on a magnetically controlled micro-pump coupled with draining catheters. LymphoDrain was developed by Dr. Marco Pisano and Dr. Valentina Triacca, in the Laboratory of Lymphatic and Cancer Bioengineering led by Prof. Melody Swartz. Since the initial invention, a multidisciplinary and highly qualified team has participated in the project bringing clinical perspective and attracting financial support from several organizations (CTI grant, FIT grant, AIT innovation grant). The recognition has been received at both national (Winner of Venture Kick stage I and II, Top3 at Venture Business Plan Competition 2016) and international level (finalist at Imagine IF Accelerator 2016, Top 2 at TERMIS-EU Business Plan Competition 2016). At the moment, Lymphatica is a finalist in the MassChallenge Switzerland Awards 2017 on a trajectory of unstoppable growth and recognition. LymphoDrain technology was consciously designed as an implantable system to cover the needs of a segment of the population, estimated at more than 15 million people in Europe and US who suffer of chronic lymphedema and presently lack effective treatments. The functionality of LymphoDrain has been successfully tested in large animal models. This vision positions LymphoDrain in a unique situation to access both the European and the US health care market as a disruptive technology in the treatment of lymphedema.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LYMPHODRAIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LYMPHODRAIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.1.;H2020-EU.2.3.1.)

WIMUACT (2017)

TECHNOLOGY FOR THE IMPROVEMENT OF SPORTS PERFORMANCE IN NON-PROFESSIONAL CONTEXTS

Read More  

DIGISTONE P1 (2014)

Production and Market entry financing of Digital Concrete Screen for Outdoor Digital Signage application

Read More  

OE Scan (2018)

A next generation diagnostic device that effectively screens for breast cancer in all tissue types, without the use of ionising radiation

Read More